196 related articles for article (PubMed ID: 35082402)
21. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
22.
Teh JLF; Cheng PF; Purwin TJ; Nikbakht N; Patel P; Chervoneva I; Ertel A; Fortina PM; Kleiber I; HooKim K; Davies MA; Kwong LN; Levesque MP; Dummer R; Aplin AE
Cancer Discov; 2018 May; 8(5):568-581. PubMed ID: 29496664
[TBL] [Abstract][Full Text] [Related]
23. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
[TBL] [Abstract][Full Text] [Related]
24. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.
Chin YM; Shibayama T; Chan HT; Otaki M; Hara F; Kobayashi T; Kobayashi K; Hosonaga M; Fukada I; Inagaki L; Ono M; Ito Y; Takahashi S; Ohno S; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2022 May; 113(5):1808-1820. PubMed ID: 35201661
[TBL] [Abstract][Full Text] [Related]
25. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.
Guo X; Chen H; Zhou Y; Shen L; Wu S; Chen Y
Expert Opin Investig Drugs; 2022 Sep; 31(9):933-944. PubMed ID: 35786092
[TBL] [Abstract][Full Text] [Related]
27. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
[TBL] [Abstract][Full Text] [Related]
28. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
Wright GM; Gimbrone NT; Sarcar B; Percy TR; Gordián ER; Kinose F; Sumi NJ; Rix U; Cress WD
PLoS One; 2021; 16(6):e0252927. PubMed ID: 34138895
[TBL] [Abstract][Full Text] [Related]
29. Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment.
Liu J; Cheng M; Xu J; Liang Y; Yin B; Liang J
Immunol Invest; 2024 Apr; 53(3):437-449. PubMed ID: 38314676
[TBL] [Abstract][Full Text] [Related]
30. Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Pesch AM; Hirsh NH; Chandler BC; Michmerhuizen AR; Ritter CL; Androsiglio MP; Wilder-Romans K; Liu M; Gersch CL; Larios JM; Pierce LJ; Rae JM; Speers CW
Clin Cancer Res; 2020 Dec; 26(24):6568-6580. PubMed ID: 32967938
[TBL] [Abstract][Full Text] [Related]
31. Immune effects of CDK4/6 inhibitors in patients with HR
Scirocchi F; Scagnoli S; Botticelli A; Di Filippo A; Napoletano C; Zizzari IG; Strigari L; Tomao S; Cortesi E; Rughetti A; Marchetti P; Nuti M
EBioMedicine; 2022 May; 79():104010. PubMed ID: 35477069
[TBL] [Abstract][Full Text] [Related]
32. A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.
Tian C; Wei Y; Li J; Huang Z; Wang Q; Lin Y; Lv X; Chen Y; Fan Y; Sun P; Xiang R; Chang A; Yang S
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270034
[TBL] [Abstract][Full Text] [Related]
33. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
Wu X; Yang X; Xiong Y; Li R; Ito T; Ahmed TA; Karoulia Z; Adamopoulos C; Wang H; Wang L; Xie L; Liu J; Ueberheide B; Aaronson SA; Chen X; Buchanan SG; Sellers WR; Jin J; Poulikakos PI
Nat Cancer; 2021 Apr; 2(4):429-443. PubMed ID: 34568836
[TBL] [Abstract][Full Text] [Related]
34. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
35. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
36. Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer.
Gomes I; Gallego-Paez LM; Jiménez M; Santamaria PG; Mansinho A; Sousa R; Abreu C; Suárez EG; Costa L; Casimiro S
Cell Rep Med; 2023 Aug; 4(8):101120. PubMed ID: 37451269
[TBL] [Abstract][Full Text] [Related]
37. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
38. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
[TBL] [Abstract][Full Text] [Related]
39. CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
Migliaccio I; Bonechi M; McCartney A; Guarducci C; Benelli M; Biganzoli L; Di Leo A; Malorni L
Cancer Treat Rev; 2021 Feb; 93():102136. PubMed ID: 33360919
[TBL] [Abstract][Full Text] [Related]
40. Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells.
Li S; Zhang Y; Wang N; Guo R; Liu Q; Lv C; Wang J; Wang L; Yang QK
Cell Death Dis; 2020 Apr; 11(4):219. PubMed ID: 32249776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
